The product is expected to be available in early 2026. The Food and Drug Administration (FDA) has approved Qivigy (immune globulin intravenous [IV], human-kthm) 10% solution for the treatment of ...
QIVIGY is the realization of over 10 years of investments and internal efforts to bring a proprietary IVIG product from concept to commercialization FORT LEE, N.J., Sept. 29, 2025 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback